Safety of Janssen Ad26.COV.S and Astra Zeneca AZD1222 COVID-19 Vaccines among Mobile Phone Users in Malawi: Findings from a National Mobile-Based Syndromic Surveillance Survey, July 2021 to December 2021
by
, , ,
Lucky Makonokaya
1,*
,
Lester Kapanda
1,
Godfrey B. Woelk
2,
Annie Chauma-Mwale
3,
Louiser Upile Kalitera
1,
Harrid Nkhoma
1,
Suzgo Zimba
1,
Rachel Chamanga
1,
Cathy Golowa
1,
Rhoderick Machekano
2 and
Thulani Maphosa
1 1
Elizabeth Glaser Pediatric AIDS Foundation, Lilongwe P/Bag 2543, Malawi
2
Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC 20005, USA
3
Public Health Institute, Ministry of Health Malawi, Lilongwe P.O. Box 30377, Malawi
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2023, 20(23), 7123; https://doi.org/10.3390/ijerph20237123
Submission received: 29 June 2023
/
Revised: 18 August 2023
/
Accepted: 2 September 2023
/
Published: 30 November 2023
(This article belongs to the Section Disease Prevention)
Abstract
:The safety profiles of the Ad26.COV2.S and AZD1222 COVID-19 vaccines have not been described in the general population in Malawi. We present self-reported adverse events (AE) following the receipt of these vaccines in Malawi as part of a national syndromic surveillance survey. We conducted phone-based syndromic surveillance surveys among adults (≥18 years) with verbal consent. We used secure tablets through random digit dialing to select mobile phone numbers and collected data electronically. Survey questions included whether the respondent had received the COVID-19 vaccines, whether they had experienced any AE following vaccination, and the severity of the AE. We used multivariable analysis to identify factors associated with self-reported AE post-COVID-19 vaccination. A total of 11,924 (36.0%) out of 33,150 respondents reported receiving at least one dose of either Ad26.COV2.S or AZD1222 between July–December 2021; of those, 65.1% were female. About 49.2% of the vaccine recipients reported at least one AE, 90.6% of which were mild, and 2.6% were severe. Higher education level and concern about the safety of COVID-19 vaccines were associated with AE self-report (Adjusted Odds Ratio [AOR] 2.63 [95% CI 1.96–3.53] and 1.44, [95% CI 1.30–1.61], respectively), while male gender and older age were associated with reduced likelihood of AE self-report (AORs 0.81, [95% CI 0.75–0.88], 0.62 [95% CI 0.50–0.77], respectively). Ad26.COV2.S and AZD1222 vaccines are well-tolerated, with primarily mild and few severe AE among adults living in Malawi. Self-reporting of AE following COVID-19 vaccination is associated with gender, age, education, and concern about the safety of the vaccines. Recognizing these associations is key when designing and implementing COVID-19 vaccination communication messages to increase vaccination coverage.
1. Introduction
The novel Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection led to a remarkable disease burden globally, resulting in over 767 million registered cases and 6.9 million deaths associated with the pandemic [1]. While infection prevention and control measures such as mask-wearing in public places, hand washing, and sanitizing helped reduce the spread of the infection and resultant disease, the implementation of these measures was a challenge globally, especially in Low- and Middle-Income Countries (LMICs) [2,3]. Vaccines reduce morbidity and mortality due to COVID-19 [4,5]. In the absence of a cure, vaccines are vital in the fight against the COVID-19 pandemic [6,7]. As of 7 July 2022, the World Health Organization (WHO) had recommended ten vaccines against COVID-19 [8].
Over 12.2 billion vaccine doses have been administered globally, with 4.8 billion people fully vaccinated against COVID-19 [9]. However, there has been slow uptake of vaccines in LMIC compared to High-Income Countries (HIC) [9]. Initial lack of availability and, more recently, concern about the safety of vaccines, among other factors, have contributed to low vaccine uptake in LMICs [10,11].
Ad26.COV2.S and AZD1222 vaccines were among the early COVID-19 vaccines recommended by the WHO [12,13]. Ad26.COV2.S, an adenovirus-vectored vaccine given as a single dose, protects against moderate to severe COVID-19 with an efficacy of 66.9% [14]. AZD1222, another adenovirus-vectored vaccine, is administered in two doses with an efficacy of 74.0% [15]. Vaccine trials and early implementation studies demonstrated that these vaccines are safe, with most of the local and systemic AE reported being mild to moderate [14,15,16]. The most commonly reported AE include myalgia, fatigue, headache, pain on the injection site, and fever. Potentially life-threatening AE, such as anaphylaxis, thromboembolic events, and Guillain–Barré syndrome, are rarely associated with Ad26.COV2.S and AZD1222 vaccines [14,15,16].
The estimated population of Malawi is 17.5 million, with more than half aged below 18 years [17]. The country rolled out the COVID-19 vaccination program with the AZD1222 vaccine in March 2021, followed by the Ad26.COV2.S vaccine in September 2021 [18]. Both of these vaccines were offered free to all residents of the country who were at least 12 years old. However, based on availability, some people did not have the opportunity to choose between the two vaccines. The nation intended to vaccinate at least 60% of the population by the end of 2022. Nevertheless, despite multiple efforts by the government and other implementing partners, only about 7% of the nation’s population had been vaccinated against COVID-19 at the beginning of August 2022 [9].
In a study conducted among healthcare workers in Malawi, 71.2% of COVID-19 vaccine recipients reported mild to moderate adverse events (AE). Fear of AE was the most common reason for declining COVID-19 vaccination [19]. There remains a paucity of data on population-based studies in the region looking at vaccine safety and a lack of a national reporting system of AE following COVID-19 vaccine receipt. Assessing the tolerability of these vaccines in the local setting would help provide a better context for messages on the safety of the vaccines.
The COVID-19 syndromic surveillance study provided an opportunity to evaluate the safety of COVID-19 vaccines in a large, diverse population. This survey, involving the random calling of mobile phone numbers throughout Malawi, was initiated as a low-cost surveillance strategy to monitor the progression of the COVID-19 epidemic, given the limitations of traditional surveillance methods. We subsequently sought to include questions on vaccinations, including reported vaccine adverse events among vaccine recipients of the two vaccines available in Malawi.
2. Methods
2.1. Study Design
Between July 2020 and April 2022, the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) in Malawi, in collaboration with the Public Health Institute of Malawi (PHIM), conducted a mobile phone-based cross-sectional COVID-19 syndromic surveillance survey among adults living in Malawi with access to an active mobile phone number. However, we utilized data on COVID-19 vaccination collected between July 2021 to December 2021. Survey questions included age, gender, education, region of residence, getting vaccination if recommended, concerns about severe reactions to the vaccines, family decision-making on the vaccination, the influence of close friends and family on vaccine receipt, trust in the vaccines, thoughts on the safety of the vaccines, vaccination, number of doses received, adverse events experienced following vaccine receipt, the severity of adverse events experienced, seeking medical care due to the adverse events, and hospitalization due to the adverse events.
To gather data for our research project, we made phone calls to computer-generated random numbers belonging to the country’s two national mobile phone network providers. We identified research assistants with a background in healthcare to conduct phone-based interviews and enter the data in real-time using tablets. The research assistants were trained in conducting phone-based surveys, the study protocol, and research ethics for human subjects.
The interviews were conducted via mobile phone, and participants were given the option to choose between English or Chichewa as their preferred language for the interview. We ensured that all respondents were at least 18 years old and obtained their verbal consent before they could participate in the survey. We needed to include participants who could effectively communicate in either English or Chichewa, so individuals who could not do so were excluded from participating.
To facilitate the survey process, we developed a questionnaire in English, which was then translated into Chichewa. To ensure that the translated version retained the same meaning as the original English version, we conducted a back-translation of the questionnaire. The questionnaire was then digitized, incorporating data range and consistency checks to maintain high data quality. We conducted a pilot of the questionnaire before implementing it.
We used Android tablets with Open Data Kit (ODK) collect v1.27 software for data collection, which allowed us to capture the survey responses electronically, ensuring efficient and accurate data collection. The collected data were securely stored on an online server to maintain confidentiality and accessibility.
2.2. Sample Size
Sample size estimates were based on the primary objective of estimating the weekly rates of self-reported influenza-like or COVID-19-like illnesses (ILI/CLI). Without preliminary data on rates of ILI/CLI in Malawi, we conservatively assumed that 50% of the population had symptoms of ILI/CLI. We estimated that 1537 individuals would allow us to estimate ILI/CLI weekly rates with 2.5% precision. We planned to survey at least 2000 individuals from the general population per week. This sample size was estimated for the original survey’s primary objective. For the vaccination studies, the sample size was considered sufficient for a precision estimate of +/−5% for the commonly reported side effect of pain at the injection site [14,15,16].
2.3. Study Variables
We asked the respondents whether they had received any COVID-19 vaccines and the type of vaccine received. For this analysis, we focused on examining the self-reported adverse events that individuals experienced after receiving COVID-19 vaccines. We asked respondents whether they had any AE following their most recent dose of COVID-19 vaccines. Those who reported AE were further asked to grade the AE on a scale of mild, moderate, or severe based on their experience. This served as the outcome variable, allowing us to investigate the potential adverse events associated with the vaccination process. We considered several independent variables to explore the factors that could influence adverse events. Sociodemographic characteristics played a significant role, including gender, age, current region of residence, and the highest level of education attained. By analyzing these factors, we aimed to understand whether certain demographic groups were more susceptible to adverse events or if there were any patterns based on these characteristics. Additionally, we sought to explore participants’ concerns regarding contracting the COVID-19 disease. Another important independent variable was the participants’ thoughts on the safety of COVID-19 vaccines. Furthermore, we considered the participants’ final say on vaccine receipt, which reflected their decision-making authority regarding vaccination. By understanding the extent of individuals’ autonomy in deciding whether to receive the vaccine, we could evaluate if this factor had any impact on the occurrence of adverse events. By examining these independent variables, we aimed to understand the factors influencing the self-reporting of adverse events following COVID-19 vaccine receipt. This analysis would provide valuable insights into the vaccine’s safety profile and help inform future vaccination campaigns and policies.
2.4. Statistical Analysis
Data analysis was performed using STATA v16. Frequencies and proportions were used to summarize the distribution of categorical demographic characteristics of COVID-19 vaccine recipients and the characteristics of respondents who reported having adverse events among vaccine recipients. Medians and interquartile ranges were used to summarize continuous variables such as age.
Pearson’s Chi-square test was used to test for potential associations between self-reported adverse events and various covariates. We used multivariable logistic regression to determine the factors independently associated with reported adverse reactions among vaccine recipients, adjusting for gender, age, current region of residence, the highest level of education attained, concern about getting COVID-19 disease, thoughts on the safety of COVID-19 vaccines, and final say on COVID-19 vaccine receipt. All the independent variables were included in the multivariate model.
2.5. Ethical Considerations
The Malawi National Health Sciences Research Committee (protocol number 22/06/2537) and Advarra Institutional Review Board (protocol number Pro00045270) in the United States of America (USA) approved the study. We obtained verbal informed consent from all study participants.
3. Results
We made 189,425 calls between July and December 2021; 67.3% (n = 127,511) were active numbers. Nearly 39.4% (n = 50,235) of the active numbers were answered; 67.1% (n = 33,688) were eligible for study participation. All of the eligible respondents consented to study participation, 98.2% (n = 33,080) of whom completed interviews (Figure 1).
A total of 11,924 (36.0%) respondents reported receipt of at least one dose of COVID-19 vaccines. A total of 3891 respondents (32.6%) had received one dose of the AZD1222 vaccine. In contrast, 5623 (47.2%) had received two doses of the AZD1222 vaccine, and 2409 (20.2%) respondents had received the Ad26.COV2.S vaccine (Figure 2).
Most of the vaccine recipients (65.1%) were female. The median age was 38 years, and the interquartile range (IQR) was 29–47 years. Approximately 42% of vaccine recipients had attained secondary education, and 44.6% resided in the central region (Table 1).
Overall, 49.2% of the respondents who received the vaccines reported at least one AE following COVID-19 vaccine receipt. There were significant differences in self-reporting of AE among different sociodemographic groups: more females (52.6%) than males (47.4%), more adults aged 35–44 years (52.8%) than those aged 18–24 (45.5%), and more who had attained tertiary education (60.4%) than those with no formal education (36.1%). The incidence of AE in respondents who received Ad26.COV2.S vaccine was 99% (n = 2385) versus 16.9% (n = 656) in those who received the first dose of AZD1222 and 50.2% (n = 2823) in those who received the second dose of AZD1222 (Table 2).
The most commonly reported AE were joint pain (45.5%), fever (26.7%), headache (26.1%), pain at the injection site (24.4%), and fatigue (16.6%). Other reported AE (>1%) included chills (15.7%), dizziness (7.6%), nausea (3.9%), and wheezing (1.4%). Approximately 90.6% of the reported AE were mild, 6.8% were moderate, and 2.6% were severe. There were no significant differences in those who sought medical care or were hospitalized by gender or age. A total of 320 (5.6%) participants were treated as outpatients following AE, 41 (0.7%) reported being hospitalized, and 5408 (93.7%) did not seek any medical attention following the AE (Table 3).
In a multivariate analysis, males were less likely to report post-vaccination AE compared to females (Adjusted Odds Ratio (AOR) 0.81, 95% Confidence Interval (CI) 0.75–0.88). Respondents aged 25–34 years (AOR = 1.24, 95% CI 1.09–1.41) and 35–44 years (AOR = 1.31, 95% CI 1.15–1.50) had increased odds of reported AE following COVID-19 vaccine receipt compared to those aged 18–24 years. However, respondents aged 65 years or older had lower odds of reporting AE than 18–24-year-olds (AOR = 0.62, 95% CI 0.50–0.77). The odds of post-vaccination AE were higher in participants with secondary (AOR = 1.62, 95% CI 1.22–2.18) and tertiary education (AOR = 2.63 (95% CI 1.96–3.53) compared to those with no formal education. Respondents who were residing in the southern region had increased odds of reporting AE post-COVID-19 vaccination than those residing in the northern region. Respondents who thought COVID-19 vaccines were unsafe were more likely to report AE (AOR = 1.44, 95% CI 1.27–1.64) compared to those who believed the vaccines were safe (Table 4).
4. Discussion
Our study showed that the Ad26.COV2.S and AZD1222 vaccines are generally well-tolerated among the adult population with phone ownership in Malawi. Nearly half of the respondents who reported receipt of at least one dose of the COVID-19 vaccines had AE. There were no significant differences in the most commonly reported AE between those who received the first and second doses of AZD1222 and those who received Ad26.COV2.S. Most respondents had mild AE following the COVID-19 vaccine receipt and never sought medical treatment following the adverse events. Joint pain, fever, headache, pain at the injection site, and fatigue were the most commonly reported post-vaccination AE. These findings are similar to those of phase 3 trials and other studies conducted in the region [15,16,20]. Potentially life-threatening AE, including anaphylaxis, thromboembolic events, and Guillain–Barré syndrome, have been reported in the phase 3 trials and in other studies conducted in the sub-Saharan region [15,16,21]. However, these AE were not reported in our study. Patients who experience such AE are more likely to seek medical attention, and improved post-vaccination AE reporting systems are needed in health facilities across the country to help monitor these events.
Self-reports of post-vaccination AE varied across demographic characteristics. Females were more likely to report AE compared to males, which was similar to other studies [15,20,22]. Females have demonstrated more robust immune systems and greater immune responses following vaccine receipt than males at all stages of life [23,24]. There may have been underreporting of AE from the males due to the poor health-seeking behavior demonstrated by males in this region [25]; however, the scope of this study could not evaluate this characteristic. The possible underreporting of adverse events among males could be due also to gender role expectations, where males are expected to be “strong” and to feel less pain and discomfort in the face of illness [25,26].
Similar to other studies, older age was associated with a reduced likelihood of post-vaccination AE [20,27]. These findings were expected because older people have weaker immune systems, leading to lower antibody titers and lower reactogenicity rates than younger people. Self-report of AE also increased with an increased level of education. We hypothesize this may be due to increased awareness of AE because those who are more educated are more likely to know about AE and subsequently more likely to report the symptom as an AE. It may also be due to better overall health-seeking behavior demonstrated by those who are more educated when compared to those who are less educated [28,29,30].
More respondents who received the second dose of AZD1222 reported post-vaccination AE compared to the first dose, similar to findings from other studies [31,32]. This pattern is observed often because the first dose serves as a primer to the immune system, and the second dose serves as a booster to enhance and further strengthen the immune response. It is also worth noting that only about one-fifth of the respondents who received one dose of AZD1222 reported adverse events, which was significantly lower than in other studies. Our findings may be partly explained by the respondents’ increased awareness of the vaccine and its side effects, which would have been better among those receiving the second dose than the first one. There may also have been differences in durations between the first and second doses, leading to differences in vaccine receipt immunogenicity [33,34]; however, this factor was not measured in our study.
The likelihood of reporting post-vaccination AE was also associated with the perception of the safety of the vaccines. Respondents who thought vaccines were unsafe were more likely to report adverse events than those who thought they were safe. We hypothesize that the participants’ thoughts of the vaccine’s safety may have been influenced by their experience of post-vaccination adverse events, which would give perceptions of vaccines being unsafe if they had more adverse events and vice versa.
We recognize the limitations of our study. First, the study was based on self-reporting, with no other data sources to triangulate with, predisposing it to recall and social desirability bias. Second, the distribution of the respondents’ demographic characteristics mirrored that of the country’s mobile phone ownership, with more males than females and most respondents aged between 25 and 44 years [35], compared to the country’s population profile of 51% female, and about half under 18 years [17]. Also, our study respondents were more likely to reside in urban areas because mobile phone ownership is higher in urban areas than in rural areas [35]. Hence, the findings need to be generalized with caution. However, due to random sampling and the large sample size, different demographic characteristics were well-represented.
5. Conclusions
Fewer AE were reported among an adult population living in Malawi following receipt of Ad26.COV2.S and AZD1222 vaccines than reported in phase 3 trials. Female gender, younger age, higher level of education, and concern about the safety of the vaccines were associated with an increased likelihood of post-vaccination adverse events. Recognizing these associations is critical when designing and implementing COVID-19 vaccination communication messages to increase vaccination coverage.
Author Contributions
Conceptualization: T.M., A.C.-M., R.M. and G.B.W. Data Curation: L.U.K., H.N. and R.M. Formal Analysis: L.U.K., H.N. and R.M. Funding Acquisition: R.M. and G.B.W. Investigation: S.Z., L.M., L.K., R.C. and C.G. Methodology: L.K., L.M., H.N., L.U.K., T.M., A.C.-M., R.C., S.Z., C.G., R.M. and G.B.W. Project Administration: T.M., A.C.-M., R.C., L.K., S.Z. and L.M. Resources: H.N., L.U.K. and L.K. Software: H.N. Supervision: T.M. Validation: L.K. and G.B.W. Visualization: L.M., L.U.K. and G.B.W. Writing—Original Draft Preparation: L.M., L.K., T.M. and G.B.W. Writing—Review and Editing: L.M., L.K., T.M., A.C.-M., L.U.K., H.N., R.M., S.Z., C.G., R.C. and G.B.W. All authors have read and agreed to the published version of the manuscript.
Funding
This surveillance work was supported by the President’s Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) under the terms of Cooperative Agreement Number U2UGH002010. Its contents are solely the authors’ responsibility and do not necessarily represent the official views of PEPFAR or the CDC. The findings and conclusions in this paper are those of the authors and do not necessarily represent the views of their supporting or funding agencies.
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki, and approved by the Malawi National Health Sciences Research Committee (NHSRC) (protocol number 22/06/2537 dated 19 June 2020) and Advarra Institutional Review Board (protocol number Pro00045270 dated 15 June 2020) in the United States of America (USA).
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
The data presented in this study are available on request from the corresponding author. The data are not publicly available due to the study protocol’s standard operating procedures on data management and storage, in accordance with the Foundation’s and NHSRC’s guidelines.
Acknowledgments
The author team is grateful to the Government of Malawi for providing this syndromic surveillance system platform. We also acknowledge support from the Malawi Ministry of Health, Department of HIV/AIDS, Public Health Institute of Malawi (PHIM), the PEPFAR/CDC team in Malawi and Atlanta, and EGPAF Malawi for their technical role and leadership in establishing the syndromic surveillance system. Finally, we would like to thank our research assistants for tirelessly conducting the interviews and for their prudent data collection.
Conflicts of Interest
The authors declare no conflict of interest.
References
- World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/data (accessed on 11 July 2023).
- Ditekemena, J.D.; Nkamba, D.M.; Muhindo, H.M.; Siewe, J.N.F.; Luhata, C.; Van den Bergh, R.; Kitoto, A.T.; Van Damme, W.; Muyembe, J.J.; Colebunders, R. Factors Associated with Adherence to COVID-19 Prevention Measures in the Democratic Republic of the Congo (DRC): Results of an Online Survey. BMJ Open 2021, 11, e043356. Available online: https://bmjopen.bmj.com/content/11/1/e043356 (accessed on 13 June 2022). [CrossRef] [PubMed]
- McMahonid, D.E.; Peters, G.A.; Iversid, L.C.; Freemanid, E.E. Global Resource Shortages during COVID-19: Bad News for Low-income Countries. PLoS Negl. Trop. Dis. 2020, 14, e0008412. Available online: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0008412 (accessed on 13 June 2022).
- Hodgson, S.H.; Mansatta, K.; Mallett, G.; Harris, V.; Emary, K.R.W.; Pollard, A.J. What Defines an Efficacious COVID-19 Vaccine? A Review of the Challenges Assessing the Clinical Efficacy of Vaccines against SARS-CoV-2. Lancet Infect. Dis. 2021, 21, e26–e35. Available online: https://pubmed.ncbi.nlm.nih.gov/33125914/ (accessed on 17 August 2022). [CrossRef] [PubMed]
- World Health Organization. Coronavirus Disease (COVID-19): Herd Immunity, Lockdowns and COVID-19. Available online: https://www.who.int/news-room/questions-and-answers/item/herd-immunity-lockdowns-and-covid-19 (accessed on 22 June 2022).
- Wang, W.; Wu, Q.; Yang, J.; Dong, K.; Chen, X.; Bai, X.; Chen, X.; Chen, Z.; Viboud, C.; Ajelli, M.; et al. Global, Regional, and National Estimates of Target Population Sizes for COVID-19 Vaccination: Descriptive Study. BMJ 2020, 371, m4704. Available online: https://www.bmj.com/content/371/bmj.m4704 (accessed on 22 June 2022). [CrossRef]
- Siedner, M.J.; Alba, C.; Fitzmaurice, K.P.; Gilbert, R.F.; Scott, J.A.; Shebl, F.M.; Ciaranello, A.; Reddy, K.P.; Freedberg, K.A. Cost-effectiveness of COVID-19 Vaccination in Low- and Middle-Income Countries. medRxiv 2021. Available online: https://www.medrxiv.org/content/10.1101/2021.04.28.21256237v1 (accessed on 6 June 2022).
- World Health Organization. Status of COVID-19 Vaccines within WHO EUL/PQ Evaluation Process. 2022. Available online: https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_07July2022.pdf (accessed on 8 August 2022).
- World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard|WHO Coronavirus (COVID-19) Dashboard with Vaccination Data. Available online: https://covid19.who.int/?mapFilter=vaccinations (accessed on 3 August 2022).
- Moola, S.; Gudi, N.; Nambiar, D.; Dumka, N.; Ahmed, T.; Sonawane, I.R.; Kotwal, A. A Rapid Review of Evidence on the Determinants of and Strategies for COVID-19 Vaccine Acceptance in Low- and Middle-Income Countries. J. Glob. Health 2021, 11, 05027. Available online: https://pubmed.ncbi.nlm.nih.gov/34912550/ (accessed on 27 July 2022). [CrossRef]
- Gozzi, N.; Chinazzi, M.; Dean, N.E.; Longini, I.M., Jr.; Halloran, M.E.; Perra, N.; Vespignani, A. Estimating the impact of COVID-19 vaccine inequities: A modeling study. Nat. Commun. 2023, 14, 3272. [Google Scholar] [CrossRef]
- World Health Organization (WHO). Interim Recommendations for the Use of the Janssen Ad26.COV2.S (COVID-19) Vaccine: Interim Guidance, First Issued 17 March 2021, Updated 15 June 2021, Updated 9 December 2021, Updated 6 June 2022. World Health Organization. License: CC BY-NC-SA 3.0 IGO. Available online: https://apps.who.int/iris/handle/10665/355160 (accessed on 27 July 2022).
- World Health Organization (WHO). Interim Recommendations for Use of the ChAdOx1-S [Recombinant] Vaccine against COVID-19 (AstraZeneca COVID-19 Vaccine AZD1222, SII Covishield, SK Bioscience). World Health Organization. 2022, pp. 1–8. Available online: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1 (accessed on 27 July 2022).
- Sadoff, J.; Gray, G.; Vandebosch, A.; Cárdenas, V.; Shukarev, G.; Grinsztejn, B.; Goepfert, P.A.; Truyers, C.; Fennema, H.; Spiessens, B.; et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19. N. Engl. J. Med. 2021, 384, 2187–2201. [Google Scholar] [CrossRef]
- Falsey, A.R.; Sobieszczyk, M.E.; Hirsch, I.; Sproule, S.; Robb, M.L.; Corey, L.; Neuzil, K.M.; Hahn, W.; Hunt, J.; Mulligan, M.J.; et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine. N. Engl. J. Med. 2021, 385, 2348–2360. Available online: https://pubmed.ncbi.nlm.nih.gov/34587382/ (accessed on 29 July 2022). [CrossRef]
- Takuva, S.; Takalani, A.; Seocharan, I.; Yende-Zuma, N.; Reddy, T.; Engelbrecht, I.; Faesen, M.; Khuto, K.; Whyte, C.; Bailey, V.; et al. Safety Evaluation of the Single-Dose Ad26.COV2.S Vaccine among Healthcare Workers in the Sisonke Study in South Africa: A Phase 3b Implementation Trial. PLoS Med. 2022, 19, e1004024. Available online: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004024 (accessed on 14 July 2022). [CrossRef]
- National Statistical Office. Malawi Population and Housing Census Report—2018. 2018 Malawi Population and Housing Main Report. 2019. Available online: https://malawi.unfpa.org/sites/default/files/resource-pdf/2018%20Malawi%20Population%20and%20Housing%20Census%20Main%20Report%20%281%29.pdf (accessed on 29 July 2022).
- World Health Organization. Malawi Marks One Year of COVID-19 Vaccination, 828,080 People Receive Full Dose|WHO|Regional Office for Africa. 2022. Available online: https://www.afro.who.int/countries/malawi/news/malawi-marks-one-year-covid-19-vaccination-828-080-people-receive-full-dose (accessed on 8 August 2022).
- Moucheraud, C.; Phiri, K.; Whitehead, H.S.; Songo, J.; Lungu, E.; Chikuse, E.; Phiri, S.; van Oosterhout, J.J.; Hoffman, R.M. Uptake of the COVID-19 vaccine among healthcare workers in Malawi. Int. Health 2023, 15, 77–84. [Google Scholar] [CrossRef]
- Beatty, A.L.; Peyser, N.D.; Butcher, X.E.; Cocohoba, J.M.; Lin, F.; Olgin, J.E.; Pletcher, M.J.; Marcus, G.M. Analysis of COVID-19 Vaccine Type and Adverse Effects following Vaccination. JAMA Netw. Open 2021, 4, e2140364. Available online: https://pubmed.ncbi.nlm.nih.gov/34935921/ (accessed on 27 July 2022). [CrossRef] [PubMed]
- Takuva, S.; Takalani, A.; Garrett, N.; Goga, A.; Peter, J.; Louw, V.; Opie, J.; Jacobson, B.; Sanne, I.; Gail-Bekker, L.; et al. Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study. N. Engl. J. Med. 2021, 385, 570–571. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190951/ (accessed on 29 July 2022). [CrossRef] [PubMed]
- Niekrens, V.; Esse, J.; Held, J.; Knobloch, C.S.; Steininger, P.; Kunz, B.; Seggewies, C.; Bogdan, C. Homologous COVID-19 BNT162b2 mRNA Vaccination at a German Tertiary Care University Hospital: A Survey-Based Analysis of Reactogenicity, Safety, and Inability to Work among Healthcare Workers. Vaccines 2022, 10, 650. Available online: https://pubmed.ncbi.nlm.nih.gov/35632406/ (accessed on 27 July 2022). [CrossRef] [PubMed]
- El Aidaoui, K.; Benhamou, R.A.; Haoudar, A.; Ziati, J.; Kantri, A.; Agrad, K.; El Kettani, C. Sex Differences in COVID-19 Outcomes. Cureus 2022, 14, e25760. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268490/ (accessed on 27 July 2022). [CrossRef] [PubMed]
- Kleina, S.L.; Marriott, I.; Fish, E.N. Sex-Based Differences in Immune Function and Responses to Vaccination. Trans. R. Soc. Trop. Med. Hyg. 2015, 109, 9–15. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4447843/ (accessed on 27 July 2022). [CrossRef] [PubMed]
- Chikovore, J.; Hart, G.; Kumwenda, M.; Chipungu, G.A.; Desmond, N.; Corbett, L. Control, Struggle, and Emergent Masculinities: A Qualitative Study of Men’s Care-Seeking Determinants for Chronic Cough and Tuberculosis Symptoms in Blantyre, Malawi. BMC Public Health 2014, 14, 1053. Available online: https://pubmed.ncbi.nlm.nih.gov/25301572/ (accessed on 2 June 2022). [CrossRef]
- Chikovore, J.; Hart, G.; Kumwenda, M.; Chipungu, G.A.; Corbett, L. “For a mere cough, men must just chew Conjex, gain strength, and continue working”: The provider construction and tuberculosis care-seeking implications in Blantyre, Malawi. Glob. Health Action 2015, 8, 26292. [Google Scholar] [CrossRef]
- Ramasamy, M.N.; Minassian, A.M.; Ewer, K.J.; Flaxman, A.L.; Folegatti, P.M.; Owens, D.R.; Voysey, M.; Aley, P.K.; Angus, B.; Babbage, G.; et al. Safety and Immunogenicity of ChAdOx1 nCoV-19 Vaccine Administered in a Prime-Boost Regimen in Young and Old Adults (COV002): A Single-Blind, Randomised, Controlled, Phase 2/3 Trial. Lancet 2020, 396, 1979. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674972/ (accessed on 27 July 2022). [CrossRef]
- Obsa, M.S.; Daga, W.B.; Wosene, N.G.; Gebremedhin, T.D.; Edosa, D.C.; Dedecho, A.T.; Awoke, N.; Weji, B.G.; Bekele, E.E. Treatment Seeking Delay and Associated Factors among Tuberculosis Patients Attending Health Facility in Ethiopia from 2000 to 2020: A Systematic Review and Meta Analysis. PLoS ONE 2021, 16, e0253746. Available online: https://pubmed.ncbi.nlm.nih.gov/34197515/ (accessed on 29 July 2022). [CrossRef]
- Koltai, D.C.; Dunn, T.W.; Smith, P.J.; Sinha, D.D.; Bobholz, S.; Kaddumukasa, M.; Teuwen, D.E. Sociocultural Determinants and Patterns of Healthcare Utilization for Epilepsy Care in Uganda. Epilepsy Behav. 2021, 114, 107304. Available online: https://pubmed.ncbi.nlm.nih.gov/32768344/ (accessed on 29 July 2022). [CrossRef]
- Christian, C.; Burger, C.; Claassens, M.; Bond, V.; Burger, R. Patient Predictors of Health-Seeking Behaviour for Persons Coughing for More Than Two Weeks in High-Burden Tuberculosis Communities: The Case of the Western Cape, South Africa. BMC Health Serv. Res. 2019, 19, 160. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417175/ (accessed on 29 July 2022). [CrossRef] [PubMed]
- Al Khames Aga, Q.A.; Alkhaffaf, W.H.; Hatem, T.H.; Nassir, K.F.; Batineh, Y.; Dahham, A.T.; Shaban, D.; Al Khames Aga, L.A.; Agha, M.Y.; Traqchi, M. Safety of COVID-19 vaccines. J. Med. Virol. 2021, 93, 6588–6594. [Google Scholar] [CrossRef] [PubMed]
- Logunov, D.Y.; Dolzhikova, I.V.; Shcheblyakov, D.V.; Tukhvatulin, A.I.; Zubkova, O.V.; Dzharullaeva, A.S.; Kovyrshina, A.V.; Lubenets, N.L.; Grousova, D.M.; Erokhova, A.S.; et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021, 397, 671–681. [Google Scholar] [CrossRef] [PubMed]
- Flaxman, A.; Marchevsky, N.G.; Jenkin, D.; Aboagye, J.; Aley, P.K.; Angus, B.; Belij-Rammerstorfer, S.; Bibi, S.; Bittaye, M.; Cappuccini, F.; et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: A substudy of two randomised controlled trials (COV001 and COV002). Lancet 2021, 398, 981–990. Available online: https://pubmed.ncbi.nlm.nih.gov/34480858/ (accessed on 29 July 2022). [CrossRef] [PubMed]
- Voysey, M.; Costa Clemens, S.A.; Madhi, S.A.; Weckx, L.Y.; Folegatti, P.M.; Aley, P.K.; Angus, B.; Baillie, V.L.; Barnabas, S.L.; Bhorat, Q.E.; et al. Single-Dose Administration and the Influence of the Timing of the Booster Dose on Immunogenicity and Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Pooled Analysis of Four Randomised Trials. Lancet 2021, 397, 881–891. Available online: https://pubmed.ncbi.nlm.nih.gov/33617777/ (accessed on 29 July 2022). [CrossRef] [PubMed]
- National Statistical Office (NSO). National Survey on Access and Use of Information and Communications Technologies by Households and Individuals in Malawi 2019. 2020. Available online: http://www.nsomalawi.mw/images/stories/data_on_line/economics/ICT/ICT Household Survey 2019.pdf (accessed on 16 August 2023).
Figure 1.
Enrollment cascade of the COVID-19 syndromic surveillance study respondents, July 2021 to December 2021.
Figure 1.
Enrollment cascade of the COVID-19 syndromic surveillance study respondents, July 2021 to December 2021.
Figure 2.
Flow of participants who self-reported COVID-19 vaccine receipt during syndromic surveillance survey between July 2021 and December 2021.
Figure 2.
Flow of participants who self-reported COVID-19 vaccine receipt during syndromic surveillance survey between July 2021 and December 2021.
Table 1.
Distribution of demographic characteristics of COVID-19 vaccine recipients between July and December 2021 (n = 11,924).
Table 1.
Distribution of demographic characteristics of COVID-19 vaccine recipients between July and December 2021 (n = 11,924).
| Variable | Frequency n (%) |
|---|---|
| Gender | |
| Female | 4165 (34.9%) |
| Male | 7759 (65.1%) |
| Age range | |
| (Median Age: 38, IQR: 29, 47) | |
| 18–24 | 1493 (12.5%) |
| 25–34 | 3263 (27.4%) |
| 35–44 | 3298 (27.7%) |
| 45–54 | 2340 (19.6%) |
| 55–64 | 993 (8.3%) |
| 65+ | 537 (4.5%) |
| Level of Education | |
| No Education | 209 (1.8%) |
| Primary | 3330 (28.1%) |
| Secondary | 4955 (41.7%) |
| Tertiary | 3378 (28.5%) |
| missing | 52 |
| Region of Residence | |
| Northern | 1943 (16.3%) |
| Central | 5323 (44.6%) |
| Southern | 4658 (39.1%) |
| Type of Vaccine | |
| AZD1222 1st Dose | 3891 (32.6%) |
| AZD1222 2nd Dose | 5623 (47.2%) |
| Ad26.COV2.S | 2409 (20.2%) |
| missing | 1 |
| Concern about getting COVID-19 disease | |
| Little Concerned | 2548 (21.4%) |
| Very Concerned | 9376 (78.6%) |
| Thoughts on the Safety of COVID-19 Vaccines | |
| Safe | 10,218 (85.7%) |
| Not safe | 1706 (14.3%) |
| Final say on Vaccine receipt | |
| Self | 10,469 (87.8%) |
| Spouse | 909 (7.6%) |
| Parents/In-laws | 359 (3%) |
| Children | 62 (0.5%) |
| Someone else | 125 (1.1%) |
Table 2.
Characteristics of respondents who reported adverse events among those who received the COVID-19 vaccine.
Table 2.
Characteristics of respondents who reported adverse events among those who received the COVID-19 vaccine.
| Variable | Frequency n (%) | p-Value |
|---|---|---|
| Gender | ||
| Female | 2188 (52.6%) | <0.01 |
| Male | 3676 (47.4%) | |
| Age range | ||
| 18–24 | 678 (45.5%) | <0.01 |
| 25–34 | 1719 (52.7%) | |
| 35–44 | 1743 (52.8%) | |
| 45–54 | 1117 (47.8%) | |
| 55–64 | 430 (43.3%) | |
| 65+ | 177 (33%) | |
| Level of Education | ||
| No Education | 75 (36.1%) | <0.01 |
| Primary | 1338 (40.2%) | |
| Secondary | 2390 (48.2%) | |
| Tertiary | 2041 (60.4%) | |
| Region of Residence | ||
| Northern | 881 (45.3%) | <0.01 |
| Central | 2659 (50.0%) | |
| Southern | 2324 (49.9%) | |
| Type of Vaccine | ||
| AZD1222 1st Dose | 656 (16.9%) | <0.01 |
| AZD1222 2nd Dose | 2823 (50.2%) | |
| Ad26.COV2.S | 2385 (99.0%) | |
| Concern about getting COVID-19 disease | ||
| Little Concerned | 1211 (47.5%) | 0.06 |
| Very Concerned | 4653 (49.7%) | |
| Thoughts on the Safety of COVID-19 Vaccines | ||
| Safe | 4875 (47.7%) | <0.01 |
| Not safe | 989 (58.0%) | |
| Final say on Vaccine receipt | ||
| Self | 5088 (48.6%) | 0.01 |
| Spouse | 494 (54.4%) | |
| Parents/In-laws | 182 (50.7%) | |
| Children | 33 (53.2%) | |
| Someone else | 67 (53.6%) |
Table 3.
Adverse events after COVID-19 vaccine receipt, the severity of adverse events, medical treatment, and hospitalizations according to gender and age groups.
Table 3.
Adverse events after COVID-19 vaccine receipt, the severity of adverse events, medical treatment, and hospitalizations according to gender and age groups.
| Variables | Total | Gender | Age Range | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Female (n = 2188) | Male (n = 3676) | 18–24 (n = 678) | 25–34 (n = 1719) | 35–44 (n = 1743) | 45–54 (n = 1117) | 55–64 (n = 430) | 65+ (n = 177) | ||
| Adverse Events | |||||||||
| Joint pain | 2668 (45.5%) | 1012 (46.3%) | 1656 (45.1%) | 303 (44.7%) | 802 (46.7%) | 815 (46.8%) | 501 (44.9%) | 184 (42.8%) | 63 (35.6%) |
| Fever | 1566 (26.7%) | 569 (26.0%) | 997 (27.1%) | 162 (23.9%) | 497 (28.9%) | 479 (27.5%) | 287 (25.7%) | 100 (23.3%) | 41 (23.2%) |
| Headache | 1529 (26.1%) | 650 (29.7%) | 879 (23.9%) | 177 (26.1%) | 456 (26.5%) | 457 (26.2%) | 290 (26.0%) | 112 (26.1%) | 37 (20.9%) |
| Pain at the injection site | 1430 (24.4%) | 550 (25.1%) | 880 (23.9%) | 187 (27.6%) | 375 (21.8%) | 432 (24.8%) | 290 (26.0%) | 103 (24.0%) | 43 (24.3%) |
| Fatigue | 975 (16.6%) | 312 (14.3%) | 663 (18.0%) | 152 (22.4%) | 323 (18.8%) | 256 (14.7%) | 162 (14.5%) | 59 (13.7%) | 23 (13.0%) |
| Chills | 918 (15.7%) | 378 (17.3%) | 540 (14.7%) | 112 (16.5%) | 300 (17.5%) | 265 (15.2%) | 176 (15.8%) | 47 (10.9%) | 18 (10.2%) |
| Dizziness | 446 (7.6%) | 194 (8.9%) | 252 (6.9%) | 66 (9.7%) | 147 (8.6%) | 116 (6.7%) | 83 (7.4%) | 25 (5.8%) | 9 (5.1%) |
| Nausea | 227 (3.9%) | 122 (5.6%) | 105 (2.9%) | 27 (4.0%) | 58 (3.4%) | 75 (4.3%) | 47 (4.2%) | 14 (3.3%) | 6 (3.4%) |
| wheezing | 82 (1.4%) | 34 (1.6%) | 48 (1.3%) | 21 (3.1%) | 25 (1.5%) | 17 (1.0%) | 13 (1.2%) | 2 (0.5%) | 4 (2.3%) |
| Other | 367 (6.3%) | 155 (7.1%) | 212 (5.8%) | 41 (6.1%) | 102 (5.9%) | 105 (6.0%) | 77 (6.9%) | 28 (6.5%) | 14 (7.9%) |
| The Severity of Adverse Events | |||||||||
| Mild | 5229 (90.6%) | 1923 (88.9%) | 3306 (91.6%) | 585 (88.5%) | 1496 (88.5%) | 1569 (91.1%) | 1013 (91.9%) | 399 (94.1%) | 167 (96.5%) |
| Moderate | 397 (6.8%) | 160 (7.4%) | 237 (6.6%) | 46 (7.0%) | 148 (8.8%) | 120 (7.0%) | 60 (5.4%) | 19 (4.5%) | 4 (2.3%) |
| Severe | 147 (2.6%) | 81 (3.7%) | 66 (1.8%) | 30 (4.5%) | 47 (2.8%) | 33 (1.9%) | 29 (2.6%) | 6 (1.4%) | 2 (1.2%) |
| Treated as outpatients | 320 (5.6%) | 125 (5.8%) | 195 (5.4%) | 45 (6.8%) | 98 (5.8%) | 96 (5.6%) | 59 (5.3%) | 15 (3.5%) | 7 (4.0%) |
| Hospitalized | 41 (0.7%) | 18 (0.8%) | 23 (0.6%) | 9 (1.4%) | 13 (0.8%) | 11 (0.6%) | 4 (0.4%) | 2 (0.5%) | 2 (1.2%) |
| Did not seek any health care service | 5408 (93.7%) | 2020 (93.4%) | 3606 (94%) | 607 (91.8%) | 1580 (93.4%) | 1612 (93.8%) | 1038 (94.3%) | 407 (96%) | 164 (94.8%) |
Data presented as number (%).
Table 4.
Factors associated with reported adverse events among COVID-19 vaccine recipients (Logistic regression).
Table 4.
Factors associated with reported adverse events among COVID-19 vaccine recipients (Logistic regression).
| Variable | Adverse Event = Yes n (%) | Unadjusted Odds Ratio (95% CI) | p Value | Adjusted Odds Ratio (95% CI) | p Value |
|---|---|---|---|---|---|
| Gender | |||||
| Female | 2188 (52.3%) | Ref | 1 | ||
| Male | 3676 (47.4%) | 0.81 (0.75–0.88) | <0.01 | 0.81 (0.75–0.88) | <0.01 |
| Age range | |||||
| 18–24 | 678 (45.5%) | Ref | 1 | ||
| 25–34 | 1719 (52.68%) | 1.34 (1.18–1.51) | <0.01 | 1.24 (1.09–1.41) | <0.01 |
| 35–44 | 1743 (52.9%) | 1.34 (1.19–1.52) | <0.01 | 1.31 (1.15–1.50) | <0.01 |
| 45–54 | 1117 (47.8%) | 1.1 (0.96–1.25) | 0.17 | 1.12 (0.98–1.29) | 0.09 |
| 55–64 | 430 (43.3%) | 0.92 (0.78–1.08) | 0.29 | 0.97 (0.82–1.15) | 0.75 |
| 65+ | 177 (33%) | 0.59 (0.48–0.72) | <0.01 | 0.62 (0.50–0.77) | <0.01 |
| Level of Education | |||||
| No Education | 75 (36.1%) | Ref | 1 | ||
| Primary | 1338 (40.2%) | 1.19 (0.89–1.59) | 0.24 | 1.19 (0.88–1.60) | 0.25 |
| Secondary | 2390 (48.2%) | 1.65 (1.24–2.2) | <0.01 | 1.62 (1.22–2.18) | <0.01 |
| Tertiary | 2041 (60.4%) | 2.71 (2.02–3.62) | <0.01 | 2.63 (1.96–3.53) | <0.01 |
| Region | |||||
| Northern | 881 (45.3%) | Ref | 1 | ||
| Central | 2659 (50%) | 1.20 (1.08–1.34 | <0.01 | 1.13 (0.99–1.29) | 0.07 |
| Southern | 2324 (49.9%) | 1.20 (1.08–1.34) | <0.01 | 1.12 (1.05–1.37) | <0.01 |
| Concern about getting COVID-19 disease | |||||
| Little Concerned | 1211 (47.5%) | Ref | 1 | ||
| Very Concerned | 4653 (49.7%) | 1.09 (1.36–1.68) | 0.06 | 1.06 (0.97–1.17) | 0.17 |
| Thoughts on the Safety of COVID-19 Vaccines | |||||
| Safe | 4875 (47.7%) | Ref | 1 | ||
| Not safe | 989 (58%) | 0.91 (0.88–0.95) | <0.01 | 1.44 (1.30–1.61) | <0.01 |
| Final say on Vaccine receipt | |||||
| Self | 5088 (48.6%) | Ref | 1 | ||
| Spouse | 494 (54.4%) | 1.26 (1.10–1.44) | <0.01 | 1.26 (1.10–1.45) | <0.01 |
| Parents/In-laws | 182 (50.7%) | 1.08 (0.88–1.34) | 0.44 | 1.14 (0.91–1.42) | 0.25 |
| Children | 33 (53.2%) | 1.20 (0.73–1.98) | 0.47 | 1.39 (0.84–1.74) | 0.3 |
| Someone else | 67 (53.6%) | 1.22 (0.85–1.74) | 0.27 | 1.21 (0.84–1.74) | 0.37 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Makonokaya, L.; Kapanda, L.; Woelk, G.B.; Chauma-Mwale, A.; Kalitera, L.U.; Nkhoma, H.; Zimba, S.; Chamanga, R.; Golowa, C.; Machekano, R.; et al. Safety of Janssen Ad26.COV.S and Astra Zeneca AZD1222 COVID-19 Vaccines among Mobile Phone Users in Malawi: Findings from a National Mobile-Based Syndromic Surveillance Survey, July 2021 to December 2021. Int. J. Environ. Res. Public Health 2023, 20, 7123. https://doi.org/10.3390/ijerph20237123
AMA Style
Makonokaya L, Kapanda L, Woelk GB, Chauma-Mwale A, Kalitera LU, Nkhoma H, Zimba S, Chamanga R, Golowa C, Machekano R, et al. Safety of Janssen Ad26.COV.S and Astra Zeneca AZD1222 COVID-19 Vaccines among Mobile Phone Users in Malawi: Findings from a National Mobile-Based Syndromic Surveillance Survey, July 2021 to December 2021. International Journal of Environmental Research and Public Health. 2023; 20(23):7123. https://doi.org/10.3390/ijerph20237123
Chicago/Turabian StyleMakonokaya, Lucky, Lester Kapanda, Godfrey B. Woelk, Annie Chauma-Mwale, Louiser Upile Kalitera, Harrid Nkhoma, Suzgo Zimba, Rachel Chamanga, Cathy Golowa, Rhoderick Machekano, and et al. 2023. "Safety of Janssen Ad26.COV.S and Astra Zeneca AZD1222 COVID-19 Vaccines among Mobile Phone Users in Malawi: Findings from a National Mobile-Based Syndromic Surveillance Survey, July 2021 to December 2021" International Journal of Environmental Research and Public Health 20, no. 23: 7123. https://doi.org/10.3390/ijerph20237123
APA StyleMakonokaya, L., Kapanda, L., Woelk, G. B., Chauma-Mwale, A., Kalitera, L. U., Nkhoma, H., Zimba, S., Chamanga, R., Golowa, C., Machekano, R., & Maphosa, T. (2023). Safety of Janssen Ad26.COV.S and Astra Zeneca AZD1222 COVID-19 Vaccines among Mobile Phone Users in Malawi: Findings from a National Mobile-Based Syndromic Surveillance Survey, July 2021 to December 2021. International Journal of Environmental Research and Public Health, 20(23), 7123. https://doi.org/10.3390/ijerph20237123
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
